Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
Impact
If enacted, HB2554 would modify existing pricing structures by altering the baseline year for rebate calculations from October 1, 2021, to October 1, 2016. This change means that the basis for calculating these rebates would reflect older pricing, likely resulting in more favorable outcomes (i.e., lower costs) for consumers. The amendments are expected to be applicable starting October 1, 2025, with provisions designed to yield more substantial savings on medications in the long run. Consequently, this bill is anticipated to provide financial relief for both public health programs and families purchasing medications out-of-pocket.
Summary
House Bill 2554, also known as the Lower Drug Costs for Families Act, aims to amend Title XVIII of the Social Security Act by applying prescription drug inflation rebates to drugs provided in the commercial market. This proposal is intended to alleviate the burden of high drug costs on American families, offering a framework that could potentially lead to significant reductions in the prices residents pay for prescription medications. By enhancing rebate mechanisms, the bill seeks to ensure that inflationary increases in drug prices are countered effectively, thereby maintaining fair access to affordable healthcare for the public.
Contention
There may be notable points of contention regarding the bill, primarily concerning the implications it holds for pharmaceutical manufacturers. Critics may argue that altering rebate structures could introduce challenges for drug supply stability and innovation within the pharmaceutical industry. Some stakeholders in the industry might view this move as a potential encroachment on pricing freedom, potentially arguing that it could stifle investment in research and development for new medications. Proponents, however, contend that the primary focus should be on making healthcare more attainable, particularly in light of rising drug costs.
Related bill
Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Establishes a pilot program on the referenced rate for prescription drugs; relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.
Establishes a pilot program on the referenced rate for prescription drugs; relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.
Amends the law on drug coverage to require insurance plans that provide coverage for prescription drugs to offer two options for prescription delivery.
Prohibiting certain health insurers from requiring cost-sharing for nonopioid prescription drugs or providing less favorable coverage for such drug than that for opioid or narcotic prescription drugs for the treatment of pain.